Outcomes of penile sarcomatoid squamous cell carcinoma from a single tertiary referral centre: a matched cohort study
BJU International · 2023
DOI: 10.1111/bju.16044 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift BJU International, 2023. Verfasst von Karl H Pang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Male Genital Cancer Centre, Institute of Andrology, University College London Hospitals NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Penile Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Objective
To report the oncological survival outcomes of men with penile sarcomatoid squamous cell carcinoma (sSCC). Patients and Methods A retrospective analysis of men with penile sSCC diagnosed between January 2010 and January 2020 in a single centre was conducted. Disease‐specific (DSS), recurrence‐free (RFS) and metastasis‐free (MFS) survival were evaluated. Outcomes were compared with a non‐sarcomatoid penile SCC cohort matched to age, type of surgery and tumour stage. Kaplan–Meier plots were used to estimate survival outcomes.
Results
In all, 1286 men were diagnosed with penile SCC during the study period and of these 38 (3%) men had sSCC. The median (interquartile range) age and follow‐up was 70 (57–81) years and 16 (7–44) months, respectively. Operations performed included: circumcision, one (2.6%); wide local excision, four (10.5%); glansectomy, 11 (29%); partial penectomy, 10 (26%); subtotal/total penectomy, 12 (32%). The Kaplan–Meier estimated 12‐, 24‐ and 36‐month DSS was 62% (vs non‐sarcomatoid, 67%), 43% (vs non‐sarcomatoid, 67%) and 36% (vs non‐sarcomatoid, 67%), respectively ( P = 0.03). The Kaplan–Meier estimated 12‐ and 24‐month RFS was 47% (vs non‐sarcomatoid, 60%) and 28% (vs non‐sarcomatoid, 55%), respectively ( P = 0.01). The MFS was 52% (vs non‐sarcomatoid, 62%) at 12 months and 37% (vs non‐sarcomatoid, 57%) at 24 months ( P = 0.04).
Conclusions
Sarcomatoid differentiation was associated with a lower DSS, RFS and MFS. Due to the rarity of its incidence and aggressiveness, expert histological review and multidisciplinary management is required in a specialist penile cancer centre.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Male Genital Cancer Centre, Institute of Andrology, University College London Hospitals NHS Foundation Trust, London, UK.
- Division of Surgery and Interventional Science, University College London, London, UK.
- Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
- Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK.
- Department of Urology, Royal Berkshire NHS Foundation Trust, Reading, UK.
- Department of Urology, Royal Surrey NHS Foundation Trust, Guildford, UK.
ORCID-Profile: Karl H Pang, Asif Muneer, Constantine Alifrangis, Hussain M Alnajjar
Zitieren
APA
Pang, K. H., Girling, B., Osinibi, E., Sawhney, P., Haider, A., Freeman, A., Hadway, P., Nigam, R., Rees, R., Mitra, A., Muneer, A., Alifrangis, C., & Alnajjar, H. M. (2023). Outcomes of penile sarcomatoid squamous cell carcinoma from a single tertiary referral centre: a matched cohort study. BJU International. https://doi.org/10.1111/bju.16044
Vancouver
Pang KH, Girling B, Osinibi E, Sawhney P, Haider A, Freeman A, et al. Outcomes of penile sarcomatoid squamous cell carcinoma from a single tertiary referral centre: a matched cohort study. BJU International. 2023. doi:10.1111/bju.16044
BibTeX
@article{Pang2023,
author = {Pang, Karl H and Girling, Benedict and Osinibi, Elizabeth and Sawhney, Paramvir and Haider, Aiman and Freeman, Alex and Hadway, Paul and Nigam, Raj and Rees, Rowland and Mitra, Anita and Muneer, Asif and Alifrangis, Constantine and Alnajjar, Hussain M},
title = {Outcomes of penile sarcomatoid squamous cell carcinoma from a single tertiary referral centre: a matched cohort study},
journal = {BJU International},
year = {2023},
doi = {10.1111/bju.16044}
}
EUVIMED